Acesso livre
Acesso livre

Emergências e Terapia Intensiva

Série de casos com 139 adolescentes e adultos jovens com suspeita de miocardite após vacina de mRNA mostrou que a maioria deles teve curso clínico leve e resolução rápida dos sintomas.

7 Dez, 2021 | 11:46h

Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults – Circulation

Comunicado de imprensa: Young people recover quickly from rare myocarditis side effect of COVID-19 vaccine – American Heart Association

Cuidado de idosos e pessoas que necessitam de cuidados paliativos com COVID-19: orientação da Australian National COVID-19 Clinical Evidence Taskforce.

7 Dez, 2021 | 11:41h

Care of older people and people requiring palliative care with COVID-19: guidance from the Australian National COVID-19 Clinical Evidence Taskforce – Medical Journal of Australia

Diretriz IDSA sobre o tratamento de infecções por enterobactérias produtoras de AmpC betalactamase, Acinetobacter baumannii resistente a carbapenêmicos e Stenotrophomonas maltophilia.

7 Dez, 2021 | 11:36h

Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections – Clinical Infectious Diseases

Diretriz S2k | Diagnóstico e tratamento do envenenamento por monóxido de carbono.

7 Dez, 2021 | 11:35h

S2k guideline diagnosis and treatment of carbon monoxide poisoning – German Medical Science

Revisão clínica | Tratamento da pneumonia em pacientes criticamente doentes.

7 Dez, 2021 | 11:33h

Management of pneumonia in critically ill patients – The BMJ

Ensaios clínicos randomizados na terapia intensiva: passado, presente e futuro.

3 Dez, 2021 | 11:00h

Randomised clinical trials in critical care: past, present and future – Intensive Care Medicine

 

Comentário no Twitter

 

Estudo de coorte retrospectivo | A maioria dos medicamentos imunossupressores, com exceção do rituximabe, não foi associada com risco aumentado de uso de ventilação mecânica ou morte em pacientes internados com Covid-19.

2 Dez, 2021 | 11:32h

Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative – The Lancet Rheumatology

Comentários:

What does endemic COVID-19 mean for the future of rituximab? – The Lancet Rheumatology

Outcomes for hospitalized COVID-19 patients taking immunosuppressive medications similar to non-immunosuppressed patients, study finds – Johns Hopkins University Bloomberg School of Public Health

Study: Immune-suppressed not at higher risk of poor COVID outcomes – CIDRAP

 

Comentário no Twitter

 

Revisão de evidência atual | Fluvoxamina para tratamento precoce da infecção por SARS-CoV-2.

2 Dez, 2021 | 11:30h

Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence – Drugs

Conteúdos relacionados:

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

Com dados de dispositivos móveis (wearable data), um sistema de alerta em tempo real pode ser útil na detecção precoce de Covid-19 e outros eventos estressores.

1 Dez, 2021 | 15:41h

Real-time alerting system for COVID-19 and other stress events using wearable data – Nature Medicine

Comentário: Scientists develop a smartwatch-based device for early detection of COVID-19 – News Medical

 

Comentário no Twitter

 

Painel do FDA recomenda (por pouco) a autorização da primeira pílula antiviral para tratar COVID-19.

1 Dez, 2021 | 15:39h

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID – STAT

Ver também: An FDA panel supports Merck COVID drug in mixed vote – NPR

Conteúdos relacionados:

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.